Oppenheimer & CO Inc Regulus Therapeutics Inc. Transaction History
Oppenheimer & CO Inc
- $6.43 Billion
- Q1 2025
A detailed history of Oppenheimer & CO Inc transactions in Regulus Therapeutics Inc. stock. As of the latest transaction made, Oppenheimer & CO Inc holds 55,000 shares of RGLS stock, worth $151,800. This represents 0.0% of its overall portfolio holdings.
Number of Shares
55,000Holding current value
$151,800% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding RGLS
# of Institutions
70Shares Held
53.6MCall Options Held
13.7KPut Options Held
7K-
Federated Hermes, Inc. Pittsburgh, PA12.9MShares$35.5 Million0.05% of portfolio
-
Nea Management Company, LLC Timonium, MD6.47MShares$17.9 Million0.73% of portfolio
-
Vivo Capital, LLC Palo Alto, CA5MShares$13.8 Million1.54% of portfolio
-
Octagon Capital Advisors LP New York, NY4.85MShares$13.4 Million1.71% of portfolio
-
Black Rock Inc. New York, NY3.97MShares$11 Million0.0% of portfolio
About Regulus Therapeutics Inc.
- Ticker RGLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 14,634,400
- Market Cap $40.4M
- Description
- Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-thre...